CAPNETZ network of competence, foundation, study
3 activities – one goal: no chance for CAP
The purpose of the foundation CAPNETZ STIFTUNG (CAP, community-acquired pneumonia) is to advance academic research on community-acquired pneumonia and other lower respiratory tract infections. Through the CAPNETZ databases and networks fundamental, microbiological, and clinical research are facilitated to investigate prevention, diagnostics and therapy management on CAP.
CAPNETZ CLINICIAN SCIENTIST PROGRAM
If you're an early-career physician getting specialized medical training (Facharztausbildung) and want to boost your career by gaining hands-on research experience in community-acquired pneumonia (CAP) diseases, you can apply for this program.
The fellowships are intended to relieve clinician scientists from their medical duties (usually around 50%; flexible) and help to establish a multidisciplinary research program by taking advantage of resources, mentoring and collaboration opportunities within the CAPNETZ network.
In the long term, this will pave the way for habilitation and the establishment of an independent research group focusing on CAP and other respiratory infectious diseases. We are aiming to support three fellows in 2025. The maximum total funding is up to €50,000 per fellow for a period of 12 months.
This funding can also be spread over two years if clinical work needs to be interspersed. Based on promising research results and a successful follow-up application, the 1-year funding period may be extended with additional funding. The application process has two stages. The deadline for submitting preliminary application as a one PDF document via e-mail to science@capnetz.de is Friday 31st of January 2025, 11:59 p.m.
INFO WEBINAR - CAPNETZ CLINICIAN SCIENTIST PROGRAM
Virtual conference to introduce the Clinician Scientist Program and CAPNETZ
COMPETENCE NETWORK
The competence network CAPNETZ was established in 2001 by the German ministry of education and research (BMBF, Bundesministerium für Bildung und Forschung) and has been expanding ever since. Physicians and researchers in Germany and Europe take part in this interdisciplinary collaboration towards new knowledge and inquiries on CAP and other acute respiratory infections. Improvements in disease management and better outcomes for patients and the healthcare system are brought about by the transfer of knowledge into medical practice.
CAPNETZ STUDY
The CAPNETZ study is a prospective multi-central observational study on community-acquired pneumonia. After two decades of patient recruitments the CAPNETZ study encompasses comprehensive data and biomaterials of over 14 000 CAP patients. These data and biomaterials form the basis for downstream research questions and constitute informative value for the national S3 guideline on CAP covering epidemiology, diagnosis, therapy and management of the disease.
RESEARCH FUNDING
The CAPNETZ STIFTUNG acts as a foundation which supports clinical and fundamental research as well as applied biomedical research on community-acquired pneumonia and other infections of the lower respiratory tract. Furthermore, every form of observational as well as clinical study (prevention, vaccination, diagnostic and therapeutic studies) can be conducted using the well established study project infrastructure of the foundation.
Interested researchers can formally request access to patient data and biomaterials, or collaborate with CAPNETZ STIFTUNG in implementation and data management of novel study projects.
The CAPNETZ STIFTUNG is associated partner of the German centre for lung research (DZL). The DZL was founded in 2011 as one of six German national centres for health research which are carried by BMBF and the federal state they are located in. Within the multi-disciplinary collaborative framework of the DZL innovative therapies and solutions for lung diseases are developed by leading researchers and physicians. As part of this collaborative effort CAPNETZ STIFTUNG contributes and receives support in terms of research and study infrastructure and public funding.